CD274 and ovarian carcinoma: In the phase III JAVELIN Ovarian 200 trial evaluating avelumab, a PD-L1 inhibitor, in combination with chemotherapy in patients with platinum-resistant or refractory ovarian cancer, the trial did not achieve its primary endpoint of improving overall survival [22].